Scilex Holding (SCLX) Stock
Small cap specialty pharmaceutical company focused on pain management. Here's the price, business snapshot, and what's worth knowing about Scilex Holding in October 2026.
Scilex Holding Co (SCLX) is a small‑cap speciality pharmaceutical company (market capitalisation roughly $101.84M). It is best known for focusing on therapies in the pain management space and related niche indications, where progress hinges on clinical development, regulatory decisions and commercial execution. For investors, SCLX represents a higher‑risk, higher‑volatility opportunity: meaningful share‑price moves often follow trial readouts, FDA actions or partnership news. Financial health, cash runway and potential dilution are important considerations alongside the science. Because the company is smaller and less liquid than large caps, trading can be choppy and spreads wider. This summary is educational only and not investment advice; it’s important to review the company’s filings, investor presentations and independent research, and to consider your own risk tolerance and time horizon before making decisions. Past performance is not indicative of future results.
Scilex Holding (SCLX) Stock Forecast
Analyst price target, next 12 months
$14.50
+257.1% vs today's $4.06
Price range over the last 12 months
Close to its 12-month low
Analysts covering Scilex Holding have a consensus 12-month target of $14.50, above the current price of $4.06.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying SCILEX stock, anticipating it will rise to a target price of $14.5.
Financial Health
SCILEX is producing solid revenue and profits, with healthy cash flow supporting its operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and regulatory steps can be primary value drivers; timing of results often drives short‑term moves, though outcomes can vary.
Small‑cap Volatility
With a market cap near $102M, the stock can be more volatile and less liquid than larger peers, so position size and risk management matter.
Regulatory Watch
Approvals, label changes or partnerships influence commercial prospects; regulatory uncertainty is a standard risk in this sector.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
